Espace privéDéconnexion
Email 
Mot de passe 

principales publications 2015

1.Anota A, Mouillet G, Trouilloud I, Dupont-Gossart A.C., Artru P, Lecomte T, Zaanan A, Gauthier M, Fein F, Dubreuil O, Paget-Bailly S, Taieb J, Bonnetain F. Sequential FOLFIRI.3 + Gemcitabine improves health-related quality of life deterioration-free survival of patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. PLoS One. 2015 May 26;10(5)

2.Anota A, Hamidou Z, Paget-Bailly S, Chibaudel B, Bascoul-Mollevi C, Auquier P, Westeel V, Fiteni F, Borg C, Bonnetain F. Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization? Qual Life Res. 2015 Jan;24(1):5-18

3.Dialla PO, Chu WO, Roignot P, Bone-Lepinoy MC, Poillot ML, Coutant C, Arveux P, Dabakuyo-Yonli TS. Impact of age-related socio-economic and clinical determinants of quality of life among long-term breast cancer survivors. Maturitas. 2015 Jul;81(3):362-70.

4.Diouf M, Bonnetain F, Barbare J-C, Bouché O, Dahan L, Paoletti X, Filleron T. Optimal Cut Points for Quality of Life Questionnaire-Core 30 (QLQ-C30) Scales: Utility for Clinical Trials and Updates of Prognostic Systems in Advanced Hepatocellular Carcinoma. The Oncologist 2015; 20(1):62-71. Epub 2014 Dec 26.

5.Filleron T, Bonnetain F, Mancini J, Martinez A, Roché H, Dalenc F. Prospective construction and validation of a prognostic score to identify patients who benefit from third-line chemotherapy for metastatic breast cancer in terms of overall survival: the METAL3 Study. Contemp Clin Trials. 2015 Jan;40:1-8. Epub 2014 Nov 8.

6.Fiteni F, Anota A, Westeel V, Bonnetain F. Health-related quality of life in phase III cancer clinical trials: from questionnaire administration to statistical analysis. Bull Cancer. 2015 Apr;102(4):360-6.

7.Fiteni F, Pam A, Anota A, Vernerey D, Paget-Bailly S, Westeel V, Bonnetain F. Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology. Expert Rev Anticancer Ther. 2015;15(8):885-91.

8.Le Rhun É, Taillibert S, Blonski M, Jouniaux Delbez N, Delgadillo D, Taillia H, Auquier P, Belin C, Bonnetain F, Varin D, Tallet A, Taillandier L. [Supportive care, cognition and quality of life in brain metastases]. Cancer Radiother. 2015 Feb;19(1):55-60.

9.Neuzillet C, Vergnault M, Bonnetain F, Hammel P. Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trial. Trials. 2015 Oct 12;16:454.

10.Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, de la Fouchardière C, Hammel P, Lecomte T, Dréanic J, Coriat R, Bachet JB, Dubreuil O, Marthey L, Dahan L, Tchoundjeu B, Locher C, Lepère C, Bonnetain F, Taieb J. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer. 2015 Sep 29;113(7):989-95. Epub 2015 Sep 15

11.Rotonda C, Anota A, Mercier M, Bastien B, Lacoste G, Limacher J.M., Quoix E, Bonnetain F. Impact of TG4010 vaccine on Health-Related Quality of life in advanced non-small-cell lung cancer: results of a phase IIB clinical trial. PLoS One. 2015 Jul 24;10(7)


Nos partenaires

https://www.ligue-cancer.net/